ACM
RCKT icon

Atika Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Atika Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-125,000
Closed -$2.19M – 88
2019
Q1 		$2.19M Buy
+125,000
New +$1.97M 0.45% 66

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Atika Capital Management's RCKT Position: Q1 2021 in Review

Atika Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q1 2021, closing a stake of 69,000 shares — an estimated $3.78M sold.

Atika Capital Management first reported a position in RCKT in Q2 2019 and held it in 2 quarters. The position peaked at $3.78M in Q4 2020. 173 funds tracked by Wall St. Rank hold RCKT as of Q1 2021.

  • Atika Capital Management reported no remaining Rocket Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Atika Capital Management sold 69,000 Rocket Pharmaceuticals shares in Q1 2021, an estimated $3.78M.
  • Atika Capital Management first reported a position in Rocket Pharmaceuticals in Q2 2019 and held it in 2 quarters.
  • Atika Capital Management's Rocket Pharmaceuticals position peaked at $3.78M in Q4 2020.
  • 173 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2021.

Based on Atika Capital Management's 13F filing for Q1 2021, filed 14 May 2021.